MDCO News and Press, The Medicines Company From 09/03/19

When pharmaceutical companies manage to get highly positive results from clinical trials of one of their more important products, then it almost always has a positive impact on the stock price, and that is what happened with MDCO stock. Solid Boost The Medicines Company (NASDAQ:MDCO) an...

Gainers:  Abeona Therapeutics (NASDAQ: ABEO ) +79% . Cidara Therapeutics (NASDAQ: CDTX ) +56% . Ardelyx (NASDAQ: ARDX ) +33% . Quorum Health Corporation (NYSE: QHC ) +21% . Net Element (NASDAQ: NETE ) +19% . Conn's (NASDAQ: CONN ) +18% . Cassava Sciences (NASDAQ: SAVA ) +15% . ...

The Medicines Company (NASDAQ: MDCO ) is up  17%  premarket on light volume in response to its announcement of positive results from a Phase 3 clinical trial, ORION-11 , evaluating inclisiran, administered twice per year, for lowering "bad" cholesterol (LDL-C) in patients with a...

-  Inclisiran achieved 54% LDL-C lowering with time-adjusted reductions of 50% sustained over 18 months of treatment -  ORION-11 study demonstrates inclisiran’s excellent safety profile, including no treatment-related liver or renal abnormalities -  Full study res...

The Medicines Co. ( MDCO ) announced that it had achieved the primary and key secondary endpoints for its late-stage study using inclisiran to treat patients with atherosclerotic cardiovascular disease ((ASCVD)) or ASCVD-risk equivalents along with elevated bad cholesterol despite maximu...

Back in May, Esperion Therapeutics ( ESPR ) announced the FDA set two PDUFA dates in February for the company's two leading products, bempedoic acid and bempedoic acid/ezetimibe combination tablet. Both of these product candidates are looking to be approved to treat elevated low-density lipo...

Shares of The Medicines Company (NASDAQ: MDCO) jumped 13.8% on Monday after the biotech announced that Orion-11, a clinical trial testing inclisiran in patients with high levels of LDL cholesterol, was successful. Interestingly, shares of  Alnylam Pharmaceuticals (NASDAQ: ALNY) , w...

Arcadia Biosciences (NASDAQ: RKDA ) +21%  on high fiber wheat deal . More news on: Arcadia Biosciences, Inc., The Medicines Company, Pitney Bowes Inc., Stocks on the move, Read more ...

The Medicines Company (NASDAQ: MDCO ) announces positive results from a Phase 3 clinical trial, ORION-11 , evaluating twice-yearly dosing of inclisiran aimed at reducing LDL-C ("bad" cholesterol) in patients with atherosclerotic cardiovascular disease. More news on: The Medicines Compan...

­ ORION-11 study met all primary and secondary efficacy endpoints with efficacy consistent with Phase 1 and 2 studies ­ Safety profile of inclisiran was at least as favorable as in ORION-1 Phase 2 and ORION-3 open-label extension studies ­ Detailed data will be presented...